Company intelligence / Profile preview

BlossomHill Therapeutics

San Diego, California, United Statesbhtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting two Phase 1/2 clinical trials: SOLARA study for BH-30643 in EGFR/HER2-mutated NSCLC (first cohort dosed in January 2025) and a trial for BH-30236 in relapsed/refractory AML and HR-MDS. BH-30643 has demonstrated promising PK and safety profile in preclinical studies, including good cardio-safety.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

BH-30643

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BlossomHill Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlossomHill Therapeutics.

Explore the full profile